AA
MIRM icon

AlphaCentric Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

AlphaCentric Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,000
Closed -$1.75M – 259
2024
Q3 		$1.75M Sell
45,000
-19,000
-30% -$758K 1.3% 23
2024
Q2 		$2.19M Sell
64,000
-30,000
-32% -$787K 1.61% 11
2024
Q1 		$2.36M Buy
94,000
+44,000
+88% +$1.21M 1.42% 18
2023
Q4 		$1.48M Buy
+50,000
New +$1.51M 0.99% 34

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCentric Advisors's MIRM Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q4 2024, closing a stake of 45,000 shares — an estimated $1.75M sold.

AlphaCentric Advisors first reported a position in MIRM in Q4 2023 and held it in 4 quarters. The position peaked at $2.36M in Q1 2024. 205 funds tracked by Wall St. Rank hold MIRM as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Mirum Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 45,000 Mirum Pharmaceuticals shares in Q4 2024, an estimated $1.75M.
  • AlphaCentric Advisors first reported a position in Mirum Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • AlphaCentric Advisors's Mirum Pharmaceuticals position peaked at $2.36M in Q1 2024.
  • 205 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.